



# Guidelines for the Minimally Invasive Treatment of Adrenal Pathology

Dimitrios Stefanidis, MD, PhD, Melanie Goldfarb, MD, Kent W. Kercher, MD, William W. Hope, MD, William Richardson, MD, Robert D. Fanelli, MD

Dimitrios Stefanidis, MD, PhD: Carolinas Medical Center, Charlotte, NC, USA

Melanie Goldfarb, MD: University of Southern California, Keck School of Medicine, Los Angeles, CA, USA

Kent W. Kercher, MD: Carolinas Medical Center, Charlotte, NC, USA

William Hope, MD, South East Area Health Education Center, Wilmington, NC, USA

William Richardson, MD: Ochsner Clinic Foundation, New Orleans, LA, USA

Robert D. Fanelli, MD: Berkshire Medical Center, Pittsfield, MA, USA

## *Corresponding Author:*

Dimitrios Stefanidis, MD, PhD, FACS

Medical Director, Carolinas Simulation Center

Division of Gastrointestinal and Minimally Invasive Surgery, Department of General Surgery

CMC Surgical Specialty Center, Suite 300

1025 Morehead Medical Plaza

Charlotte, NC 28204

Tel: (704) 355-3168

Fax: (704) 355-5114

[Dimitrios.Stefanidis@carolinashealthcare.org](mailto:Dimitrios.Stefanidis@carolinashealthcare.org)

## **Preamble**

The guidelines for the minimally invasive surgical treatment of adrenal pathology are a series of systematically developed statements to educate and guide the surgeon (and patient) in the appropriate use of minimally invasive techniques for the treatment of adrenal disease. It addresses the indications, risks, benefits, outcomes, alternatives, and controversies of the procedures used in specific clinical circumstances. The statements included in this guideline are the product of a systematic review of published work on the topic, and the recommendations are explicitly linked to the supporting evidence. The strengths and weaknesses of the available evidence are highlighted, and expert opinion is sought where published evidence lacks depth.

## **Disclaimer**

Clinical practice guidelines are intended to indicate the best available approach to medical conditions as established by a systematic review of available data and expert opinion. The approach suggested might not be the only acceptable approach given the complexity of the healthcare environment. These guidelines are intended to be flexible, as the surgeon must choose the approach best suited to the individual patient and variables in existence at the moment of decision. These guidelines are applicable to all physicians who are appropriately credentialed and address the clinical situation in question, regardless of specialty.



Guidelines are developed under the auspices of SAGES, the guidelines committee, and are approved by the Board of Governors. The recommendations of each guideline undergo multidisciplinary review and are considered valid at the time of production based on the data available. New developments in medical research and practice pertinent to each guideline are reviewed, and guidelines will be periodically updated.

## Literature Review Method

A systematic literature search was performed on MEDLINE in April 2011. The search strategy was limited to adult English language articles and is shown in [Figure 1](#).

The literature search identified 79 relevant articles. The abstracts were reviewed by four committee members (DS, WWH, MG, and KWK) and divided into the following categories:

- a. Randomized studies, meta-analyses, and systematic reviews
- b. Prospective studies
- c. Retrospective studies
- d. Case reports
- e. Review articles

Randomized controlled trials, meta-analyses, and systematic reviews were selected for further review along with prospective and retrospective studies when a higher level of evidence was lacking. For inclusion, prospective and retrospective studies had to report outcomes on at least 50 adrenalectomies. Studies with smaller samples were considered when additional evidence was lacking. The most recent reviews were also included. All case reports, old reviews, and smaller studies were excluded. Duplicate publications or patient populations were considered only once. Whenever the available evidence from Level I studies was considered to be adequate, lower evidence level studies were not considered. Newer relevant articles that were published after the original literature search date during the drafting of this guideline were also included. According to these exclusion criteria, 70 articles were selected for review.

The reviewers graded the level of evidence and searched the bibliography of each article for additional articles that may have been missed during the original search. Additional relevant articles (n=94) were obtained and included in the review for grading. A total of 164 graded articles relevant to this guideline were included in this review. To facilitate the review by multiple reviewers, these articles were divided into the following topics and distributed to the reviewers:

- Minimally invasive adrenalectomy outcomes and comparison to open
- Description and comparison of various MIS adrenalectomy techniques
- Management of large adrenal tumors
- Management of adrenal cortical carcinoma and metastatic disease
- Management of pheochromocytoma
- Other circumstances (i.e. partial and bilateral adrenalectomy, etc.)

The recommendations included in this guideline were devised based on the reviewers' grading of all articles.



## Levels of Evidence

The quality of the evidence and the strength of the recommendation for each of the guidelines were assessed according to the GRADE system. There is a 4-tiered system for quality of evidence (very low (+), low (++), moderate (+++), or high (++++)) and a 2-tiered system for strength of recommendation (weak or strong) [1-2].

## Introduction

Adrenal tumors have been found in 8.7% of autopsy series with adrenal incidentalomas being reported in 4%-7% of patients undergoing abdominal imaging studies. Adrenal pathology that requires surgical resection spans a large spectrum of diseases. A description of the presenting symptoms of adrenal disease and their diagnostic workup is beyond the scope of this guideline. Readers are referred to the existing comprehensive joint guideline by the American Association of Clinical Endocrinologists and the American Association of Endocrine surgeons (<http://endocrinesurgery.org/documents/pguidelines/AdrenalGuidelines.pdf>). This guideline focuses on minimally invasive surgical outcomes for adrenal disease and the comparison of different surgical approaches. The focus of the current guideline begins after the decision to perform an adrenalectomy has been made.

## Outcomes of minimally invasive adrenalectomy

Since the first description of a laparoscopic adrenalectomy by Michel Gagner in 1992, laparoscopic adrenalectomy has quickly become the standard of care for removing the majority of adrenal masses [1-2]. Multiple prospective and retrospective studies have demonstrated minimal morbidity, short convalescence, and excellent cosmesis with laparoscopic adrenalectomy [1, 3-30]. These results apply to functional and nonfunctional tumors. Recently, similar outcomes have been published for the pediatric and non-adrenal cancer patient populations [31-37]. Most patients spend 1-2 nights in the hospital, with a few centers performing outpatient adrenalectomies in appropriately selected patients [15, 38-39]. However, as with many technologically advanced procedures, high volume surgeons continue to have the best outcomes [40].

### *Comparison with open adrenalectomy*

Studies comparing open and laparoscopic adrenalectomy have demonstrated in the laparoscopic group improved postoperative pain levels [41-56], decreased morbidity [26, 41, 46, 57-58], lower [11, 42, 44-45, 48-49, 52-53, 59-63] or equivalent [47, 50, 54-55, 57, 64-65], operative blood loss, shorter hospital stays [11, 26, 41-48, 50-51, 57, 59, 64, 66], and quicker return of bowel function and recovery. No significant differences in mortality have been demonstrated for a procedure that in general is associated with very low mortality. Whether the open or laparoscopic approach leads to shorter operating time is less clear. Some series report longer times with the laparoscopic approach [41-42, 45-46, 48-52, 59, 64-65], others report similar duration [11, 17, 43-44, 47, 53-55, 57, 60, 62-63, 66-67], and others shorter duration [26, 61] compared with the open approach ([Table 1](#)).



Specifically for pheochromocytomas, which are generally more technically demanding resections due to the inflammatory process and increased vascularity surrounding the adrenal gland, comparative studies have reported lower estimated blood loss and postoperative length of stay for the laparoscopic approach [53-54, 56, 60-63, 65, 67]. Operative duration, morbidity, and mortality were found to be similar in the majority of published studies [53-55, 60-63, 67]. Furthermore, most studies report similar effects of the two surgical approaches on intraoperative patient hemodynamics [53, 55-56, 60, 62, 65, 67], while some have reported fewer episodes of intraoperative hypertension [54, 61] or hypotension [63] when the laparoscopic approach was used ([Table 2](#)).

Two retrospective studies comparing laparoscopic and open adrenalectomy in patients with hyperaldosteronism reported significantly decreased morbidity [57-58] and shorter length of hospital stay [57] in the laparoscopic group.

**Recommendation:** Minimally invasive adrenalectomy is associated with less postoperative pain, shorter hospital stay, earlier recovery, and similar long-term outcomes compared with open surgery and has been established as the preferred approach to all non-primary adrenal cancer pathology (+++, strong).

## Adrenalectomy techniques

Several different techniques have been proposed and are currently being used for the resection of adrenal tumors. A description of each approach as well as advantages and disadvantages are described below ([Tables 3-6](#)).

### Lateral transabdominal adrenalectomy (LTA)

LTA is the most common adrenalectomy technique used by the general surgeon [68]. Compared with the retroperitoneal approach, LTA provides greater working space that can be beneficial for very large tumors and morbidly obese patients, where use of extra-long bariatric instruments facilitates the procedure [1-2, 6-8, 24, 69-72] ([Table 3](#)). In addition, the lateral decubitus position used during this approach affords excellent exposure, since gravity pulls the abdominal contents outside the operating field. During left adrenalectomy, mobilization of the spleen medially is facilitated.

#### *Relevant technical details*

Patients are positioned at a 60-90 degree angle with tumor side up, and the table is flexed to maximally open the space between the tip of the 12th rib and the iliac crest. While variable, port positioning aims to establish instrument triangulation; the procedure can usually be accomplished with 3 ports for left adrenalectomy and 4 ports for right adrenalectomy (the fourth port is used for liver retraction). During left adrenalectomy, procedural steps include taking down the splenic flexure of the colon, freeing the splenic ligaments to mobilize the spleen and rotate it medially, and dissecting in the avascular plane between the tail of the pancreas and kidney, and controlling/dividing the adrenal vein as it enters the left renal vein. During right adrenalectomy,



procedural steps include mobilization of the right triangular ligament of the liver, a hockey stick incision between the retroperitoneal attachments of the right lobe of the liver and the lateral border of the IVC, dissection of the lateral edge of the IVC, and taking the right adrenal vein at the takeoff from the IVC. Superior retraction of the liver must be maintained by the assistant throughout the case to aid exposure of the right adrenal. Mobilization of the gland follows a superior-lateral to medial-inferior progression unless surgeon preference is for taking the adrenal vein early, in which case an inferior to superior and medial to lateral mobilization of the gland is preferred.

## **Posterior retroperitoneoscopic adrenalectomy (PRA)**

Brunt first described the concept of PRA in a porcine model in 1993 [73]. Over the next decade, Walz perfected the technique and demonstrated its safety and enhanced visualization with use of higher insufflation pressures in the retroperitoneal cavity [74]. Advocates of PRA cite advantages of direct access to the adrenal gland that avoids the intra-abdominal cavity, making it attractive in the setting of prior abdominal surgery [7, 75]. Additionally, because the prone position facilitates equal access to the right and left side, bilateral procedures performed by PRA do not require repositioning between sides [2, 9, 70]. Disadvantages include lack of access to the intra-abdominal cavity for evaluation, difficulty in removing large tumors, and increased difficulty with increasing BMI due to the large distance between the gland and the skin and decreased working space from the additional fatty tissue [9, 74]. Comparative studies with other laparoscopic approaches have demonstrated a small yet significant benefit in pain medication requirement, time to oral intake, length of hospital stay, and overall convalescence for PRA ([Table 4](#)) [7, 22, 71-72, 76-79].

### *Relevant technical details*

Patients are positioned on a rectangular support with bent hip joints at a 90-degree angle, allowing the abdominal contents to fall forward with gravity, with the table flexed to maximally open the space between the 12th rib and iliac crest. Three trocars are used for both right and left procedures, which are placed just under the 12th rib with a combination of direct palpation and finger guidance after the dorsal lumbar fascia is digitally perforated. With a balloon trocar in place in the middle port, the retroperitoneal space is insufflated with 20-30 mmHg of CO<sub>2</sub>. This high pressure insufflation starts the dissection of the space that is completed with blunt dissection of the area underneath the diaphragm and the fatty tissue above the superior border of the kidney. Landmarks that should be identified are the superior pole of kidney caudally, the paraspinous muscles medially, and the posterior surface of liver (right) or spleen (left) laterally. Dissection of the adrenal gland is facilitated by maintaining downward retraction of the kidney, and starts inferiorly in a plane close to the kidney surface. The adrenal gland can then be elevated, allowing identification and ligation of the adrenal vein in a medial or inferomedial position with either clips or a hemostatic device. Mobilization of the gland is completed by dissecting laterally between the diaphragm and the psoas; the superior attachments are divided last. An important aspect of the procedure is having the first assistant maintain the horizon of the camera throughout the case.



## Anterior transabdominal adrenalectomy (ATA)

ATA is a sub-mesocolic approach and is the least common of the techniques employed for adrenalectomy. The main appeal is the conventional abdominal laparoscopic view that is familiar to all general surgeons [19, 80]. However, operating times are generally longer, and a greater number of ports are needed for a successful operation.

### *Relevant technical details*

With the patient in the supine position, a camera port is placed at the umbilicus and three additional ports are placed in various configurations. Key steps for left adrenalectomy include elevating the transverse mesocolon, identifying the ligament of Treitz and the IMV, and opening the posterior retroperitoneum lateral to the IMV. By dissecting inferior to and elevating the pancreas, the left renal vein can be identified and followed to the left adrenal vein. After the vein is taken, the gland can be mobilized from inferior and medial to superior and lateral.

## Lateral retroperitoneoscopic adrenalectomy (LPA)

LPA is the most common technique used by the urologic surgeon for adrenalectomy likely due to the familiarity with the anatomy of laparoscopic nephrectomy. Similar to PRA, LPA is advocated in patients with prior abdominal surgery [13, 76]. While tumor size is also an important consideration, it does not seem to be as important as in PRA [24-25]. Typically, the procedure has slightly longer operating times and requires more ports than LA or PRA but maintains the advantages of avoiding the peritoneal cavity as in PRA ([Table 5](#)) [22, 81].

### *Relevant technical details*

The patient is positioned in a 60-90 degree angle with tumor side up, and the table is flexed similar to the lateral transabdominal approach. However, 4-5 trocars are needed to complete the procedure on either side. Landmarks that should be identified during the procedure are the superior pole of the kidney, parietal peritoneum, diaphragm, retroperitoneal fold, posterior renal fascia, and psoas muscle. The retroperitoneal fat outside Gerota's fascia and outside the posterior renal fascia must be cleared from inferior to the diaphragm to the iliac fossa until the fat prolapses into the fossa. A longitudinal incision in Gerota's near the diaphragm will facilitate dissection in three key planes: between the peri-renal fat and anterior renal fascia under the diaphragm, between the perirenal fat and posterior fascia on the lateral upper pole kidney, and between the adrenal gland and upper pole of the kidney. As in PRA, mobilization begins inferiorly to the gland along the superior border of the kidney, and elevation of the gland facilitates further mobilization, dividing the superior attachments last.

**Recommendations:** Several approaches to laparoscopic adrenalectomy have been described in the literature. Surgeons should choose the approach they are most familiar with, have had training in, and have the best patient outcomes with (+++, strong).

Surgeons should also take into consideration that in specific clinical circumstances some



approaches may be more beneficial than others:

- In patients with previous abdominal surgery, a retroperitoneal approach may be associated with less operative time and fewer complications (++, weak).
- For bilateral adrenalectomies, the posterior retroperitoneal approach may be advantageous, as it eliminates patient repositioning during the case (++, weak).
- In morbidly obese patients (BMI >35 kg/m<sup>2</sup>) and for large tumors (>6 cm), the lateral transabdominal approach may increase the feasibility of the procedure compared with the other approaches (++, weak).

## Robotic adrenalectomy (RA)

Since the first robotic adrenalectomy by Horgan et al in 2001 [82], several other groups have successfully adopted the robotic approach. Brunaud reported the largest series to date of lateral transabdominal RA and found that after a learning curve of 20 cases, tumor side, previous clinical experience, and the first assistant's skill are the main predictors of operative time in RA [83-84]. The authors also reported that RA might be especially useful for patients with a high BMI (>30-35 kg/m<sup>2</sup>) and large tumors (>5.5 cm). Similarly, Nordenstrom and colleagues reported advantages in obese patients and large tumors in their series with robotic RPA ([Table 6](#)) [85]. Proponents of the robotic technique cite advantages of three-dimensional depth perception, an added element of dexterity with the "wrist" action of robotic instruments, and superior ergonomic conditions for the surgeon [86]. The main disadvantages addressed by most authors were cost and the learning curve of the entire surgical team [84-85, 87-88].

From a technical aspect, all authors stress the importance of training an entire operative team. For lateral RA, robotic setup is an extreme flank position with the robotic camera axis above and lateral to the umbilicus. The robotic cart is positioned at a 45-degree angle to the table

over the head of the patient with the working axis of the robot directed toward the ipsilateral clavicle [83, 89]. For retroperitoneal RA, the table is rotated 30 degrees clockwise, and the robot is brought in from the head and positioned between the shoulders [85, 90].

**Recommendation:** Compared with standard laparoscopic techniques, robotic adrenalectomy may offer advantages for large tumors and in morbidly obese patients (+, weak). However, given the increased cost, longer operative times, and lack of clear patient outcome benefits using this technique, additional higher quality evidence is needed before a firm recommendation can be provided.

## Single port adrenalectomy

Outcomes with single incision adrenalectomy have been recently reported by several authors [91-95]. Published non-randomized series comparing conventional laparoscopic approaches and single port adrenalectomy have demonstrated no significant differences in patient length of stay or morbidity and a small benefit in cosmesis and postoperative pain but longer operative times with single port laparoscopy [96-98].



From a technical standpoint, a transabdominal single port adrenalectomy requires a 2-3 cm incision for a multiport device. Placement of the device has been described at the umbilicus, which requires extra-long instruments to reach the adrenal gland, and underneath the 12th rib for a more direct though less cosmetic location. For right adrenalectomies, an additional 2 mm needlescopic port is needed for liver retraction. With a retroperitoneal approach, specific recommendations regarding the multiport include placing the camera in the lower aperture position and using ports of different lengths [96-97]. Additionally, Walz describes the need for a more extended mobilization of the upper pole of the kidney compared with his conventional retroperitoneal approach [97].

**Recommendation:** Based on the available evidence, single port adrenalectomy is feasible and safe when undertaken by an experienced surgeon but offers little if any advantage over other standard laparoscopic approaches to adrenalectomy. Additional, better quality evidence is needed before this approach can be recommended (+, weak).

## Partial adrenalectomy

The first modern clinical use of cortical sparing adrenalectomy was described by van Heerden for the treatment of bilateral hereditary pheochromocytomas in 1985 [99]. In the hopes of sparing patients from lifelong steroid dependence and the complications of adrenal insufficiency, over the past 25 years, laparoscopic partial adrenalectomies have replaced bilateral adrenalectomies for hereditary pheochromocytomas. Recently, cortical sparing operations have been reported for unilateral functional tumors [3, 81, 100]. Perioperative outcomes using this technique do not differ from outcomes of complete adrenalectomy. Studies reporting long-term outcomes after partial adrenalectomy have showed steroid-free outcomes in up to 91% of patients [14, 70, 100-102].

There is general agreement in the literature that the location of the tumor within the gland is the main determinant of the ease and ability to perform a partial adrenalectomy. Tumors anterior to and on the margin of the gland are generally more amenable to partial removal than those on the posterior surface. In the laparoscopic and open adrenalectomy literature, the reported amount of adrenal cortical tissue needed to preserve adrenal function is 1/3 of one gland or 15% of total adrenal cortical tissue [70, 103-105]. When preparing the remnant, it is suggested that the portion of adrenal cortex that is to be preserved should not be mobilized out of the retroperitoneum to preserve the blood supply, and all tumors should be resected with a 0.5-1 cm margin of normal adrenal tissue [104, 106]. Preservation of the adrenal vein is not essential and depends on the situation [2-3, 81, 101]. Additionally, liberal use of laparoscopic ultrasound should be employed, as it is a useful adjunct to show clear differentiation of the tumor from normal tissue [2, 89, 101, 104, 107]. It should also be noted that with the exception of partial adrenalectomies, extracapsular dissection with preservation of the capsule of the adrenal gland and resection of the surrounding fatty tissue is generally recommended by experts during removal of the adrenal gland.

**Recommendations:** Partial adrenalectomy is safe and feasible in the hands of appropriately trained surgeons. For patients requiring bilateral adrenalectomy, such as for hereditary pheochromocytomas, laparoscopic cortical sparing surgery may be the procedure of choice (++),



weak).

Additional evidence is needed before a recommendation can be provided for partial adrenalectomy of single gland, non-hereditary tumors.

## **Method and timing for taking the adrenal vein**

For many years, surgeons learning the technique of open adrenalectomy were taught to take the adrenal vein early, especially in pheochromocytomas, to prevent catecholamine release during surgery that could affect the patient's hemodynamic parameters and potentially their outcomes. However, with the introduction of laparoscopic surgery, a significantly lower catecholamine surge has been described to occur [108]. This is believed to be due to the more gentle dissection and decreased gland manipulation when performed by an experienced laparoscopic surgeon. In addition, recent studies have demonstrated no difference in outcomes when the adrenal vein is taken first versus last or not at all during partial adrenalectomies [101, 109-110]. For vein control, most surgeons use metal clips, although other hemostatic devices such as the ultrasonic shears, Ligasure device, or electrothermal bipolar systems have also been used successfully. Comparative studies on the preferred type of vein control device are lacking [87, 97, 111-112].

**Recommendation:** The classic teaching for early vein control during open adrenalectomy has not been confirmed for laparoscopic adrenalectomy, because patient outcomes do not appear to be affected by early versus late ligation. Thus, the type and timing of adrenal vein control depends on surgeon preference and the specific anatomic variables associated with each case (+, weak).

## **Laparoscopic adrenalectomy for suspected or proven adrenal cortical carcinoma and adrenal metastases**

Published data comparing laparoscopic and open adrenalectomy for adrenal cortical carcinoma (ACC) are limited. Advocates for an open approach cite the higher rates of local and peritoneal recurrence in the laparoscopic group, shorter time to recurrence, and a higher incidence of positive margins [4, 113-114]. Advocates for LA argue that for stage I and II ACC tumors, LA has outcomes similar to OA when performed in a large volume referral center with surgeons strictly adhering to standard oncologic principles [18, 115-116]. Many surgeons argue that for medium and large incidental tumors without preoperative indication of malignancy, it is appropriate to start the procedure laparoscopically, but the surgeon needs to convert to open surgery when signs of tumor adhesion or invasion, enlarged lymph nodes or a difficult dissection are encountered [5-6, 117]. The third international adrenal cancer symposium highlighted the limitations of the available literature and concluded that the most important variables for good patient outcomes were an appropriate oncologic resection performed at a specialized center [115].

**Recommendations:** For ACC, the best determinant of patient outcomes is an appropriate oncologic resection that includes *en bloc* resection of any contiguous involved structures and



regional lymphadenectomy. Thus, an open approach to resection may be best. If a laparoscopic approach is chosen (due to unknown malignancy status preoperatively or suspected early stage ACC), conversion to open surgery is strongly recommended when difficult dissection is encountered due to tumor adhesion or invasion or enlarged lymph nodes are seen (++ , strong).

## **Adrenal metastases**

Laparoscopic resection of metastases to the adrenal gland is performed in increasing numbers due to two concurrent developments. First is the adoption of laparoscopic adrenalectomy as standard of care for benign adrenal tumors because of the shorter hospital stay, quicker recovery, less blood loss, and overall lower morbidity. Second, over the past few decades, there has been an overall improvement and evolution of cancer treatment in general; patients live longer with their disease and more recurrences are limited to a single site. Before laparoscopy, the risks and morbidity of performing an adrenalectomy for a solitary cancer metastases did not, in general, appear to outweigh the benefits; however, in the past 15 years, the scales have tipped in favor of laparoscopic resection.

Laparoscopic resection of a solitary adrenal metastasis in a patient with an otherwise controlled cancer is a safe procedure with a very low morbidity and seems to have similar long term outcomes in the few selected published series [32-34, 118-124]. The most common cancers that metastasize to the adrenal gland are lung, breast, kidney, melanoma, GI, and lymphoma. The largest study that directly compared laparoscopic with open resection of metastases reported on 94 patients with up to 31 months of follow-up [34]. In this series, patients that underwent laparoscopic resection had shorter operative times and lengths of stay and less blood loss and overall morbidity (including laparoscopic conversions). However, they had similar rates of positive resection margins, local and overall recurrence, and disease-free survival compared with open resection. Three other small studies that also compared laparoscopic with open resection reported similar results [118, 120, 123].

**Recommendations:** Solitary metastases to the adrenal gland without evidence of local invasion can be approached laparoscopically by a surgeon skilled in advanced laparoscopy and adrenal surgery (+, weak). If local invasion is found intraoperatively, conversion to an open approach is warranted (+, strong).

## **Laparoscopic adrenalectomy in large adrenal masses**

The use of laparoscopy for excision of large adrenal tumors is debated, and the literature on the subject is scant and retrospective in nature. As discussed in the section on laparoscopic adrenalectomy for suspected or adrenal cortical carcinoma, an open approach is recommended in patients with known or probable primary adrenal cortical carcinoma. Conversion from a

laparoscopic to open approach is also recommended in cases with intraoperative signs of carcinoma such as tumor adhesions or local invasion, enlarged lymph nodes, or a difficult dissection. The question on how to approach large adrenal tumors (>5-6 cm) with no preoperative (or intraoperative) evidence of malignancy, however, is a dilemma to the surgeon.



The overall safety of laparoscopy for large tumors without evidence of carcinoma has been reported in several small series [8, 29, 125-130]. In general, the outcome of laparoscopic adrenalectomy for large tumors is similar to small tumors with regard to operating room time [29, 128-129], hospital stay [29, 128-130], and the complication rate [29, 128, 130]; however, tumor size  $\geq 7.5$  cm has been shown to be an independent risk factor for longer operating times, more blood loss [8, 127-128], longer hospital stay [8], and a higher conversion rate to open surgery [29]. A shorter length of operating room time has been reported in patients undergoing laparoscopic adrenalectomy in tumors  $\leq 5$  cm [130].

**Recommendations:** Large adrenal tumors without pre- or intraoperative evidence of primary adrenal cortical carcinoma can be approached laparoscopically by a surgeon skilled in advanced laparoscopy and adrenal surgery (+, weak). Laparoscopic adrenalectomy for larger tumors may be associated with increased operating room times, blood loss, and conversion rate to open surgery (+, weak). If there is any evidence for carcinoma found intraoperatively, conversion to an open approach is warranted (should be strongly considered) (+, strong).

## Pheochromocytoma

Despite early concerns regarding perioperative cardiovascular complications related to pneumoperitoneum, organ manipulation, and dissection, a number of published series have demonstrated the laparoscopic approach to pheochromocytomas to be safe and effective [56, 108, 131]. Nevertheless, compared with other adrenal pathologies, minimally invasive adrenalectomy for pheochromocytoma, even for experienced surgeons, can still be associated with longer operative times, more blood loss, increased complications, and longer hospitalization [132]. The following sections highlight a number of important considerations for surgeons taking care of patients with pheochromocytoma.

### *Preoperative Care*

In patients with preoperative signs, symptoms, and biochemical evidence of catecholamine excess, alpha-adrenergic blockade should be initiated at least 10 days before surgery. Phenoxybenzamine has historically been considered the gold standard for preoperative alpha blockade. An initial dose of 10 mg PO BID can be titrated upward with regimens of 10-20 mg TID providing adequate blockade in most patients, particularly when combined with other anti-hypertensive agents that most patients are taking at baseline. Phenoxybenzamine is a long-acting alpha antagonist, and its use in higher doses has been associated with frequent side effects including nasal congestion, nausea, abdominal pain, and tachycardia. Because of this, many surgeons and endocrinologists have transitioned to the use of shorter acting alpha blockers such as doxazosin, which tend to have fewer side effects. In addition, more rapid metabolism tends to translate into less postoperative hypotension related to residual unopposed alpha blockade [133-134]. Some authors have also advocated the combined use of alpha blockers along with metyrosine, which inhibits tyrosine hydroxylase, the rate-limiting step in catecholamine synthesis. Early data suggest that this combination may limit intraoperative hemodynamic instability to a greater degree than alpha blockade alone [135-136].

The clinical endpoint for preoperative blockade is control of hypertension. Adequate



preoperative alpha blockade can be confirmed by increasing the dosage until the patient develops mild orthostatic hypotension. For patients who also suffer from tachycardia or arrhythmias, the addition of beta-adrenergic blockade should be initiated only after adequate alpha blockade has been achieved. Patients with alpha blockade-induced orthostatic hypotension should be treated with oral and/or intravenous volume loading during the 24-48 hours before surgery. All patients should also be given 1-2 liters of intravenous crystalloid solution for intravascular volume expansion before induction of general anesthesia on the day of surgery [137-142].

**Recommendations:** Before laparoscopic adrenalectomy for pheochromocytoma, alpha adrenergic receptor blockade should be considered in all patients. When used preoperatively, alpha blockade should be continued until signs of orthostatic hypotension are evident (+++, weak). Short acting alpha blockers may be preferable to long acting ones. Beta blockade should also be considered in appropriately selected patients and should only be instituted following adequate alpha blockade (++, weak).

### *Intraoperative Management*

Careful perioperative monitoring of hemodynamic status is critical to the safe resection of catecholamine producing tumors. Before the induction of general anesthesia, an arterial line should be placed. A central venous line is also recommended for infusion of vasoactive drips and monitoring of volume status. Despite appropriate preoperative medical management, intraoperative hypertension is common and is a valid concern. Continuous invasive monitoring and pharmacologic intervention by an experienced anesthesia team are necessary to avoid substantial cardiovascular instability. Drips should be prepared and ready to infuse at any point during the procedure. Hypertension is generally treated with nitroprusside, nitroglycerine, or nicardipine. Tachyarrhythmias can be managed with intravenous beta blockers and/or lidocaine[142]. Following ligation of the adrenal vein and removal of the tumor, significant hypotension can develop precipitously. Hypotension is treated with volume resuscitation and alpha-adrenergic agonists such as vasopressin. Depending on the degree of residual alpha blockade, some patients will require pressor support for hours or occasionally days following surgery.

In addition to relying on pharmacologic manipulation to treat intraoperative hypertension, there are a number of strategies that the surgeon can employ to minimize dramatic fluctuations in blood pressure during resection of pheochromocytomas. By avoiding excessive tumor manipulation, the effects of catecholamine surges can potentially be mitigated. During both open and laparoscopic adrenalectomy, tumor manipulation has been shown to be the most significant intraoperative stimulus for catecholamine release. Clinically, sudden increases in plasma catecholamine levels can result in episodes of dramatic and dangerous intraoperative hypertension that can be difficult to control even with rapid infusion of vasodilators. Intraoperative catecholamine monitoring has demonstrated that mean plasma epinephrine and norepinephrine levels can increase up to 34-fold during tumor manipulation [143-146]. Careful adrenal dissection and tumor handling are important strategies to avoid catecholamine-induced cardiovascular instability. These techniques require that the surgeon minimize direct manipulation or compression of the gland itself. In many cases, adjacent structures such as the



kidney, pancreas, and liver can be dissected and retracted away from the tumor and peri-adrenal fat and/or Gerota's fascia used as a handle such that the gland can be manipulated without actually placing direct pressure on the tumor. As mentioned earlier in this guideline, early ligation of the adrenal vein is not necessary during pheochromocytoma resection, as it has not been shown to impact hormonal release by the tumor. On the other hand, intra-abdominal insufflation during laparoscopic pheochromocytoma excision may cause an increase in serum catecholamines [147-148]. While the mechanism is unclear, the stimulus is thought to relate either to direct tumor compression or to a change in tumor perfusion. In addition, pneumoperitoneum with CO<sub>2</sub> may lead to hypercapnia and acidosis, which are known stimuli of catecholamine secretion and hypertension. As a result, helium has been suggested as an alternate insufflation agent to eliminate the deleterious effects of CO<sub>2</sub> during laparoscopic adrenalectomies for pheochromocytoma. In a prospective evaluation of 11 patients undergoing helium insufflation during laparoscopic pheochromocytoma resection, the authors demonstrated that its use avoided significant intraoperative hypercarbia or acidosis and provided greater intraoperative hemodynamic stability [143]. These data have not been substantiated by a large prospective series, and given the overall safety of CO<sub>2</sub>, most surgeons continue to use standard CO<sub>2</sub> insufflation.

In addition to the problems associated with catecholamine liberation, large size and prominent vascularity compound the challenges of removing pheochromocytomas. Compared with other indications for adrenalectomy, both laparoscopic and open resection of pheochromocytomas has been associated with longer operative times, higher complication rates, greater blood loss and longer hospitalization in some selected series [1, 149]. In general, these tumors tend to be larger than other functional and nonfunctional adrenal lesions and often have a large number of arterial and venous tributaries that bleed with minimal manipulation. Generous use of clips in addition to vessel sealing technology is advisable for reliable hemostasis. Large tumors often encroach on the renal vessels, particularly on the left side. The renal vessels must be carefully identified and protected to avoid inadvertent injury during dissection. The need to operate around the renal hilum or to perform an en bloc resection of the peri-adrenal fat along with the adrenal gland does not mandate a conversion to laparotomy. However, conversion to an open procedure is warranted when laparoscopic dissection cannot be performed safely or a complete resection cannot be performed without undue trauma to the gland. In the setting of pheochromocytoma, this determination must be based on intraoperative findings of tumor invasion into adjacent structures, since radiographic and histological information, including intraoperative frozen section examination, are unreliable predictors of malignancy [150-151].

**Recommendations:** Invasive hemodynamic monitoring should be considered during LA for pheochromocytomas (++, strong). To minimize hemodynamic instability due to catecholamine release during surgery, minimization of direct manipulation or compression of the adrenal gland is necessary (++, strong). Early ligation of the vein does not prevent hemodynamic instability (+, weak). Due to the added challenge of intraoperative hemodynamic variability, frequent communication between the surgical and anesthesia teams is important for optimal perioperative outcomes.

### *Postoperative Management*



During the immediate postoperative period, hypotension and hypoglycemia are the most common occurrences. Monitoring in an ICU setting for 24 hours postoperatively is advisable. The need for pressors or anti-hypertensive therapy postoperatively is dictated by the patient's hemodynamic status. For patients without evidence of underlying postoperative essential hypertension, all anti-hypertensive medications should be discontinued postoperatively with the possible exception of beta blockers. In patients who have been treated with long-term preoperative beta blocker therapy, postoperative management may necessitate a slow taper to avoid reflex tachycardia.

Since there are no definitive diagnostic criteria for malignancy in pheochromocytoma and the true malignant potential of pheochromocytomas is very difficult to predict, patients require long-term follow-up to confirm no recurrence. Recurrence rates in the literature following resection of benign-appearing lesions are approximately 6%-8%, and long disease-free intervals are not atypical, with recurrences often presenting several years to decades after initial surgery [150-154]. Thus, follow-up recommendations include annual blood pressure monitoring as well as serum and/or urinary metanephrines, and, in patients who demonstrate clinical signs or symptoms of recurrence, abdominal imaging is indicated [155].

Common histological features, such as capsular invasion, vascular and lymphatic penetration, nuclear atypia and mitotic activity, which almost always indicate malignancy in other tumors, do not always indicate malignancy in pheochromocytomas, nor does the lack of these pathologic features dictate that a tumor is benign. In 2002, a pheochromocytoma of the adrenal gland scaled score (PASS) was developed based on various degrees of cytologic atypia including invasion, necrosis, cellularity, mitoses, pleomorphism, and growth; a PASS score <sup>34</sup> indicated an aggressive pathology [156]. However, although the utility of PASS was replicated in one large cohort, other smaller studies did not find the PASS score useful for predicting further malignancy and advocated for further refinement [157-160]. Additionally, two recent papers indicate that tumor size, location, and urinary VMA levels are important features for anticipating tumor recurrence [161-162]. Thus, it appears that individual tumor biology rather than the surgical approach may determine the chances of cure. Nonetheless, extreme care must be taken to avoid intraoperative capsular disruptions and possible iatrogenic pheochromocytosis as small case reports have described early local recurrence of pheochromocytoma after initial laparoscopic resection and tumor spillage. In that same context, adrenal specimens removed with minimally invasive techniques should be placed in an impervious extraction bag before removal and/or morcellation.

**Recommendations:** Due to the potential for hemodynamic instability after pheochromocytoma resection, all patients should be closely monitored in the early postoperative phase (++, strong). Capsular disruptions of the adrenal gland during surgery should be avoided to minimize the risk of disease recurrence. (+, weak). Given the lack of clear predictors of malignancy to detect recurrences, patients with pheochromocytoma should be monitored long term with blood pressure measurements and serum and/or urinary metanephrine levels (++, strong).

## Learning curve

Throughout the laparoscopic literature, it is evident that extensive experience of the surgeon



and surgical team optimizes patient outcomes and cost effectiveness in the operating room. For laparoscopic and robotic adrenalectomy, the learning curve appears to be between 20 to 40 cases [1, 5, 23, 83, 153, 163]. In general practice, this number may be difficult to achieve due to the paucity of these procedures. There is controversy over which approach, anterior or posterior, requires more cases for the surgeon's operative time and patient morbidity to plateau [76-78]. Nevertheless, learning curve comparisons between different surgical approaches are difficult, as other factors such as the surgeon's previous experience and the familiarity and pre-implementation training of the operative team also significantly influence the procedure learning curve [75, 109, 152].

**Recommendations:** Minimally invasive adrenalectomy is associated with a learning curve that may be difficult to overcome given the paucity of these cases in general practice. Dedicated, advanced training should be pursued by surgeons unfamiliar with this technique. Until proficiency with laparoscopic adrenalectomy is attained, consideration should be given to referral to a center with expertise in minimally-invasive adrenal surgery (++, strong).

### **Limitations of the available literature**

The available literature on laparoscopic adrenalectomy has several limitations. Few small controlled trials are available, and most studies are retrospective in nature with significant heterogeneity among them and increased risk for publication bias and other confounding factors. In addition, reporting of outcomes varies significantly as does the follow-up period, which generally tends to be short making it difficult to combine and compare such data. Finally, the majority of the studies do not report details on the expertise of their surgeons, and most have been conducted in a single institution making the generalization of their findings difficult. Based on these limitations of the literature, firm recommendations are difficult.

### **Summary of Recommendations**

1. Minimally invasive adrenalectomy is associated with less postoperative pain, shorter hospital stay, earlier recovery, and similar long-term outcomes compared with open surgery and has been established as the preferred approach to all non-primary adrenal cancer pathology (+++, strong).
2. Several approaches to laparoscopic adrenalectomy have been described in the literature. Surgeons should choose the approach they are most familiar with, have had training in, and have the best patient outcomes with (+++, strong). Surgeons should also take into consideration that in specific clinical circumstances some surgical approaches to adrenalectomy may be more beneficial than others:
  - In patients with previous abdominal surgery, a retroperitoneal approach may be associated with less operative time and fewer complications (++, weak).
  - For bilateral adrenalectomies, the posterior retroperitoneal approach may be advantageous, as it eliminates patient repositioning during the case (++, weak).
  - In morbidly obese patients (BMI >35 kg/m<sup>2</sup>) and for large tumors (>6 cm), the lateral transabdominal approach may increase the feasibility of the procedure compared with the other approaches (++, weak).



3. Compared with standard laparoscopic techniques, robotic adrenalectomy may offer advantages for large tumors and in morbidly obese patients (+, weak). However, given the increased cost, longer operative times, and lack of clear patient outcome benefits using this technique, additional higher quality evidence is needed before a firm recommendation can be provided.
4. Based on the available evidence, single port adrenalectomy is feasible and safe when undertaken by an experienced surgeon but offers little if any advantage over other standard laparoscopic approaches to adrenalectomy. Additional, better quality evidence is needed before this approach can be recommended (+, weak).
5. Partial adrenalectomy is safe and feasible in the hands of appropriately trained surgeons. For patients requiring bilateral adrenalectomy, such as for hereditary pheochromocytomas, laparoscopic cortical sparing surgery may be the procedure of choice (++, weak). Additional evidence is needed before a recommendation can be provided for partial adrenalectomy of single gland, non-hereditary tumors.
6. The classic teaching for early vein control during open adrenalectomy has not been confirmed for laparoscopic adrenalectomy, because patient outcomes do not appear to be affected by early versus late ligation. Thus, the type and timing of adrenal vein control depends on surgeon preference and the specific anatomic variables associated with each case (+, weak).
7. For adrenocortical carcinoma, the best determinant of patient outcomes is an appropriate oncologic resection that includes *en bloc* resection of any contiguous involved structures and regional lymphadenectomy. Thus, an open approach to resection may be best. If a laparoscopic approach is chosen (due to unknown malignancy status preoperatively or suspected early stage carcinoma), conversion to open surgery is strongly recommended when difficult dissection is encountered due to tumor adhesion or invasion or enlarged lymph nodes are seen (++, strong).
8. Solitary metastases to the adrenal gland without evidence of local invasion can be approached laparoscopically by a surgeon skilled in advanced laparoscopy and adrenal surgery (+, weak). If local invasion is found intraoperatively, conversion to an open approach is warranted (+, strong).
9. Large adrenal tumors without pre- or intraoperative evidence of primary adrenal cortical carcinoma can be approached laparoscopically by a surgeon skilled in advanced laparoscopy and adrenal surgery (+, weak). Laparoscopic adrenalectomy for larger tumors may be associated with increased operating room times, blood loss, and conversion rate to open surgery (+, weak). If there is any evidence for carcinoma found intraoperatively, conversion to an open approach is warranted (should be strongly considered) (+, strong).
10. Before laparoscopic adrenalectomy for pheochromocytoma, alpha adrenergic receptor blockade should be considered in all patients. When used preoperatively, alpha blockade should be continued until signs of orthostatic hypotension are evident (+++, weak). Short acting alpha blockers may be preferable to long acting ones. Beta blockade should also be considered in appropriately selected patients and should only be instituted following adequate alpha blockade (++, weak).
11. Invasive hemodynamic monitoring should be considered during LA for pheochromocytomas (++, strong). To minimize hemodynamic instability due to catecholamine release during surgery, minimization of direct manipulation or



compression of the adrenal gland is necessary (++, strong). Early ligation of the vein does not prevent hemodynamic instability (+, weak). Due to the added challenge of intraoperative hemodynamic variability, frequent communication between the surgical and anesthesia teams is important for optimal perioperative outcomes.

12. Due to the potential for hemodynamic instability after pheochromocytoma resection, all patients should be closely monitored in the early postoperative phase (++, strong). Capsular disruptions of the adrenal gland during surgery should be avoided to minimize the risk of disease recurrence. (+, weak). Given the lack of clear predictors of malignancy to detect recurrences, patients with pheochromocytoma should be monitored long term with blood pressure measurements and serum and/or urinary metanephrine levels (++, strong).
13. Minimally invasive adrenalectomy is associated with a learning curve that may be difficult to overcome given the paucity of these cases in general practice. Dedicated, advanced training should be pursued by surgeons unfamiliar with this technique. Until proficiency with laparoscopic adrenalectomy is attained, consideration should be given to referral to a center with expertise in minimally-invasive adrenal surgery (++, strong).

## References:

1. Gagner M, Pomp A, Heniford BT, Pharand D, Lacroix A (1997) Laparoscopic adrenalectomy: lessons learned from 100 consecutive procedures. *Ann Surg* 226:238-246; discussion 246-237
2. Gumbs AA, Gagner M (2006) Laparoscopic adrenalectomy. *Best Pract Res Clin Endocrinol Metab* 20:483-499
3. Fu B, Zhang X, Wang GX, Lang B, Ma X, Li HZ, Wang BJ, Shi TP, Ai X, Zhou HX, Zheng T (2011) Long-term results of a prospective, randomized trial comparing retroperitoneoscopic partial versus total adrenalectomy for aldosterone producing adenoma. *J Urol* 185:1578-1582
4. Gonzalez RJ, Shapiro S, Sarlis N, Vassilopoulou-Sellin R, Perrier ND, Evans DB, Lee JE (2005) Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. *Surgery* 138:1078-1085; discussion 1085-1076
5. Henry JF, Defechereux T, Raffaelli M, Lubrano D, Gramatica L (2000) Complications of laparoscopic adrenalectomy: results of 169 consecutive procedures. *World J Surg* 24:1342-1346
6. Henry JF, Sebag F, Iacobone M, Mirallie E (2002) Results of laparoscopic adrenalectomy for large and potentially malignant tumors. *World J Surg* 26:1043-1047
7. Berber E, Tellioglu G, Harvey A, Mitchell J, Milas M, Siperstein A (2009) Comparison of laparoscopic transabdominal lateral versus posterior retroperitoneal adrenalectomy. *Surgery* 146:621-625; discussion 625-626
8. Castillo OA, Vitagliano G, Secin FP, Kerkebe M, Arellano L (2008) Laparoscopic adrenalectomy for adrenal masses: does size matter? *Urology* 71:1138-1141
9. Dickson PV, Jimenez C, Chisholm GB, Kennamer DL, Ng C, Grubbs EG, Evans DB, Lee JE, Perrier ND (2011) Posterior retroperitoneoscopic adrenalectomy: a contemporary American experience. *J Am Coll Surg* 212:659-665; discussion 665-657
10. Kazaryan AM, Marangos IP, Rosseland AR, Rosok BI, Villanger O, Pinjo E, Pfeiffer PF, Edwin B (2009) Laparoscopic adrenalectomy: Norwegian single-center experience of



242 procedures. *J Laparoendosc Adv Surg Tech A* 19:181-189

11. Kwan TL, Lam CM, Yuen AW, Lo CY (2007) Adrenalectomy in Hong Kong: a critical review of adoption of laparoscopic approach. *Am J Surg* 194:153-158
12. Liao CH, Lai MK, Li HY, Chen SC, Chueh SC (2008) Laparoscopic adrenalectomy using needlescopic instruments for adrenal tumors less than 5cm in 112 cases. *Eur Urol* 54:640-646
13. Lin Y, Li L, Zhu J, Qiang W, Makiyama K, Kubota Y (2007) Experience of retroperitoneoscopic adrenalectomy in 195 patients with primary aldosteronism. *Int J Urol* 14:910-913
14. Meria P, Kempf BF, Hermieu JF, Plouin PF, Duclos JM (2003) Laparoscopic management of primary hyperaldosteronism: clinical experience with 212 cases. *J Urol* 169:32-35
15. Zeh HJ, 3rd, Udelsman R (2003) One hundred laparoscopic adrenalectomies: a single surgeon's experience. *Ann Surg Oncol* 10:1012-1017
16. Meyer-Rochow GY, Soon PS, Delbridge LW, Sywak MS, Bambach CP, Clifton-Bligh RJ, Robinson BG, Sidhu SB (2009) Outcomes of minimally invasive surgery for pheochromocytoma. *ANZ J Surg* 79:367-370
17. Miccoli P, Raffaelli M, Berti P, Materazzi G, Massi M, Bernini G (2002) Adrenal surgery before and after the introduction of laparoscopic adrenalectomy. *Br J Surg* 89:779-782
18. Nocca D, Aggarwal R, Mathieu A, Blanc PM, Deneve E, Salsano V, Figueira G, Sanders G, Domergue J, Millat B, Fabre PR (2007) Laparoscopic surgery and corticoadrenomas. *Surg Endosc* 21:1373-1376
19. Perretta S, Campagnacci R, Guerrieri M, Paganini AM, De Sanctis A, Sarnari J, Rimini M, Lezoche E (2005) Sub-mesocolic access in laparoscopic left adrenalectomy. *Surg Endosc* 19:977-980
20. Shen ZJ, Chen SW, Wang S, Jin XD, Chen J, Zhu Y, Zhang RM (2007) Predictive factors for open conversion of laparoscopic adrenalectomy: a 13-year review of 456 cases. *J Endourol* 21:1333-1337
21. Soon PS, Yeh MW, Delbridge LW, Bambach CP, Sywak MS, Robinson BG, Sidhu SB (2008) Laparoscopic surgery is safe for large adrenal lesions. *Eur J Surg Oncol* 34:67-70
22. Terachi T, Yoshida O, Matsuda T, Orikasa S, Chiba Y, Takahashi K, Takeda M, Higashihara E, Murai M, Baba S, Fujita K, Suzuki K, Ohshima S, Ono Y, Kumazawa J, Naito S (2000) Complications of laparoscopic and retroperitoneoscopic adrenalectomies in 370 cases in Japan: a multi-institutional study. *Biomed Pharmacother* 54 Suppl 1:211s-214s
23. Walz MK, Alesina PF, Wenger FA, Deligiannis A, Szuczik E, Petersenn S, Ommer A, Groeben H, Peitgen K, Janssen OE, Philipp T, Neumann HP, Schmid KW, Mann K (2006) Posterior retroperitoneoscopic adrenalectomy--results of 560 procedures in 520 patients. *Surgery* 140:943-948; discussion 948-950
24. Wang B, Ma X, Li H, Shi T, Hu D, Fu B, Lang B, Chen G, Zhang X (2011) Anatomic retroperitoneoscopic adrenalectomy for selected adrenal tumors >5 cm: our technique and experience. *Urology* 78:348-352
25. Zhang X, Fu B, Lang B, Zhang J, Xu K, Li HZ, Ma X, Zheng T (2007) Technique of anatomical retroperitoneoscopic adrenalectomy with report of 800 cases. *J Urol* 177:1254-1257



26. Lee J, El-Tamer M, Schiffner T, Turrentine FE, Henderson WG, Khuri S, Hanks JB, Inabnet WB, 3rd (2008) Open and laparoscopic adrenalectomy: analysis of the National Surgical Quality Improvement Program. *J Am Coll Surg* 206:953-959; discussion 959-961
27. Morris L, Ituarte P, Zarnegar R, Duh QY, Ahmed L, Lee J, Inabnet W, 3rd, Meyer-Rochow G, Sidhu S, Sywak M, Yeh M (2008) Laparoscopic adrenalectomy after prior abdominal surgery. *World J Surg* 32:897-903
28. Nau P, Demyttenaere S, Muscarella P, Narula V, Hazey JW, Ellison EC, Melvin WS (2010) Pheochromocytoma does not increase risk in laparoscopic adrenalectomy. *Surg Endosc* 24:2760-2764
29. Parnaby CN, Chong PS, Chisholm L, Farrow J, Connell JM, O'Dwyer PJ (2008) The role of laparoscopic adrenalectomy for adrenal tumours of 6 cm or greater. *Surg Endosc* 22:617-621
30. St Peter SD, Valusek PA, Hill S, Wulkan ML, Shah SS, Martinez Ferro M, Bignon H, Laje P, Mattei PA, Graziano KD, Muensterer OJ, Pontarelli EM, Nguyen NX, Kane TD, Qureshi FG, Calkins CM, Leys CM, Baerg JE, Holcomb GW (2011) Laparoscopic adrenalectomy in children: a multicenter experience. *J Laparoendosc Adv Surg Tech A* 21:647-649
31. Kebebew E, Siperstein AE, Clark OH, Duh QY (2002) Results of laparoscopic adrenalectomy for suspected and unsuspected malignant adrenal neoplasms. *Arch Surg* 137:948-951; discussion 952-943
32. Castillo OA, Vitagliano G, Kerkebe M, Parma P, Pinto I, Diaz M (2007) Laparoscopic adrenalectomy for suspected metastasis of adrenal glands: our experience. *Urology* 69:637-641
33. Marangos IP, Kazaryan AM, Rosseland AR, Rosok BI, Carlsen HS, Kromann-Andersen B, Brennhovd B, Hauss HJ, Giercksky KE, Mathisen O, Edwin B (2009) Should we use laparoscopic adrenalectomy for metastases? Scandinavian multicenter study. *J Surg Oncol* 100:43-47
34. Strong VE, D'Angelica M, Tang L, Prete F, Gonen M, Coit D, Touijer KA, Fong Y, Brennan MF (2007) Laparoscopic adrenalectomy for isolated adrenal metastasis. *Ann Surg Oncol* 14:3392-3400
35. Toniato A, Boschini IM, Opocher G, Guolo A, Pelizzo M, Mantero F (2007) Is the laparoscopic adrenalectomy for pheochromocytoma the best treatment? *Surgery* 141:723-727
36. Lopes RI, Denes FT, Bissoli J, Mendonca BB, Srougi M (2012) Laparoscopic adrenalectomy in children. *J Pediatr Urol* 8:379-385
37. Miller KA, Albanese C, Harrison M, Farmer D, Ostlie DJ, Gittes G, Holcomb GW, 3rd (2002) Experience with laparoscopic adrenalectomy in pediatric patients. *J Pediatr Surg* 37:979-982; discussion 979-982
38. Ramirez-Plaza CP, Perales JL, Camero NM, Rodriguez-Canete A, Bondia-Navarro JA, Santoyo-Santoyo J (2011) Outpatient laparoscopic adrenalectomy: a new step ahead. *Surg Endosc* 25:2570-2573
39. Gill IS, Hobart MG, Schweizer D, Bravo EL (2000) Outpatient adrenalectomy. *J Urol* 163:717-720
40. Park HS, Roman SA, Sosa JA (2009) Outcomes from 3144 adrenalectomies in the United States: which matters more, surgeon volume or specialty? *Arch Surg*



144:1060-1067

41. Thompson GB, Grant CS, van Heerden JA, Schlinkert RT, Young WF, Jr., Farley DR, Ilstrup DM (1997) Laparoscopic versus open posterior adrenalectomy: a case-control study of 100 patients. *Surgery* 122:1132-1136
42. Brunt LM, Doherty GM, Norton JA, Soper NJ, Quasebarth MA, Moley JF (1996) Laparoscopic adrenalectomy compared to open adrenalectomy for benign adrenal neoplasms. *J Am Coll Surg* 183:1-10
43. Barreca M, Presenti L, Renzi C, Cavallaro G, Borrelli A, Stipa F, Valeri A (2003) Expectations and outcomes when moving from open to laparoscopic adrenalectomy: multivariate analysis. *World J Surg* 27:223-228
44. Wu CT, Chiang YJ, Chou CC, Liu KL, Lee SH, Chang YH, Chuang CK (2006) Comparative study of laparoscopic and open adrenalectomy. *Chang Gung Med J* 29:468-473
45. Hallfeldt KK, Mussack T, Trupka A, Hohenbleicher F, Schmidbauer S (2003) Laparoscopic lateral adrenalectomy versus open posterior adrenalectomy for the treatment of benign adrenal tumors. *Surg Endosc* 17:264-267
46. Hazzan D, Shiloni E, Golijanin D, Jurim O, Gross D, Reissman P (2001) Laparoscopic vs open adrenalectomy for benign adrenal neoplasm. *Surg Endosc* 15:1356-1358
47. Tanaka M, Tokuda N, Koga H, Kimoto Y, Naito S (2000) Laparoscopic adrenalectomy for pheochromocytoma: comparison with open adrenalectomy and comparison of laparoscopic surgery for pheochromocytoma versus other adrenal tumors. *J Endourol* 14:427-431
48. Imai T, Kikumori T, Ohiwa M, Mase T, Funahashi H (1999) A case-controlled study of laparoscopic compared with open lateral adrenalectomy. *Am J Surg* 178:50-53; discussion 54
49. Ishikawa T, Sowa M, Nagayama M, Nishiguchi Y, Yoshikawa K (1997) Laparoscopic adrenalectomy: comparison with the conventional approach. *Surg Laparosc Endosc* 7:275-280
50. Korman JE, Ho T, Hiatt JR, Phillips EH (1997) Comparison of laparoscopic and open adrenalectomy. *Am Surg* 63:908-912
51. Winfield HN, Hamilton BD, Bravo EL, Novick AC (1998) Laparoscopic adrenalectomy: the preferred choice? A comparison to open adrenalectomy. *J Urol* 160:325-329
52. Guazzoni G, Montorsi F, Bocciardi A, Da Pozzo L, Rigatti P, Lanzi R, Pontiroli A (1995) Transperitoneal laparoscopic versus open adrenalectomy for benign hyperfunctioning adrenal tumors: a comparative study. *J Urol* 153:1597-1600
53. Hemal AK, Kumar R, Misra MC, Gupta NP, Chumber S (2003) Retroperitoneoscopic adrenalectomy for pheochromocytoma: comparison with open surgery. *JSLs* 7:341-345
54. Edwin B, Kazaryan AM, Mala T, Pfeffer PF, Tonnessen TI, Fosse E (2001) Laparoscopic and open surgery for pheochromocytoma. *BMC Surg* 1:2
55. Inabnet WB, Pitre J, Bernard D, Chapuis Y (2000) Comparison of the hemodynamic parameters of open and laparoscopic adrenalectomy for pheochromocytoma. *World J Surg* 24:574-578
56. Mobius E, Nies C, Rothmund M (1999) Surgical treatment of pheochromocytomas: laparoscopic or conventional? *Surg Endosc* 13:35-39
57. Duncan JL, 3rd, Fuhrman GM, Bolton JS, Bowen JD, Richardson WS (2000) Laparoscopic adrenalectomy is superior to an open approach to treat primary



- hyperaldosteronism. *Am Surg* 66:932-935; discussion 935-936
58. Shen WT, Lim RC, Siperstein AE, Clark OH, Schechter WP, Hunt TK, Horn JK, Duh QY (1999) Laparoscopic vs open adrenalectomy for the treatment of primary hyperaldosteronism. *Arch Surg* 134:628-631; discussion 631-622
59. Chotirosnramit N, Angkoolpakdeekul T, Kongdan Y, Suvikapakornkul R, Leelaudomlipi S (2007) A laparoscopic versus open adrenalectomy in Ramathibodi Hospital. *J Med Assoc Thai* 90:2638-2643
60. Tiberio GA, Baiocchi GL, Arru L, Agabiti Rosei C, De Ponti S, Matheis A, Rizzoni D, Giulini SM (2008) Prospective randomized comparison of laparoscopic versus open adrenalectomy for sporadic pheochromocytoma. *Surg Endosc* 22:1435-1439
61. Lang B, Fu B, OuYang JZ, Wang BJ, Zhang GX, Xu K, Zhang J, Wang C, Shi TP, Zhou HX, Ma X, Zhang X (2008) Retrospective comparison of retroperitoneoscopic versus open adrenalectomy for pheochromocytoma. *J Urol* 179:57-60; discussion 60
62. Ichikawa T, Mikami K, Suzuki H, Imamoto T, Yamazaki T, Naya Y, Ueda T, Igarashi T, Ito H (2002) Laparoscopic adrenalectomy for pheochromocytoma. *Biomed Pharmacother* 56 Suppl 1:149s-153s
63. Sprung J, O'Hara JF, Jr., Gill IS, Abdelmalak B, Sarnaik A, Bravo EL (2000) Anesthetic aspects of laparoscopic and open adrenalectomy for pheochromocytoma. *Urology* 55:339-343
64. Naito S, Uozumi J, Shimura H, Ichimiya H, Tanaka M, Kumazawa J (1995) Laparoscopic adrenalectomy: review of 14 cases and comparison with open adrenalectomy. *J Endourol* 9:491-495
65. Davies MJ, McGlade DP, Banting SW (2004) A comparison of open and laparoscopic approaches to adrenalectomy in patients with phaeochromocytoma. *Anaesth Intensive Care* 32:224-229
66. Acosta E, Pantoja JP, Gamino R, Rull JA, Herrera MF (1999) Laparoscopic versus open adrenalectomy in Cushing's syndrome and disease. *Surgery* 126:1111-1116
67. Humphrey R, Gray D, Pautler S, Davies W (2008) Laparoscopic compared with open adrenalectomy for resection of pheochromocytoma: a review of 47 cases. *Can J Surg* 51:276-280
68. Assalia A, Gagner M (2004) Laparoscopic adrenalectomy. *Br J Surg* 91:1259-1274
69. Berber E, Duh QY, Clark OH, Siperstein AE (2002) A critical analysis of intraoperative time utilization in laparoscopic adrenalectomy. *Surg Endosc* 16:258-262
70. Alesina PF, Hinrichs J, Meier B, Schmid KW, Neumann HP, Walz MK (2012) Minimally invasive cortical-sparing surgery for bilateral pheochromocytomas. *Langenbecks Arch Surg* 397:233-238
71. Ramacciato G, Nigri GR, Petrucciani N, Di Santo V, Piccoli M, Buniva P, Valabrega S, D'Angelo F, Aurello P, Mercantini P, Del Gaudio M, Melotti G (2011) Minimally invasive adrenalectomy: a multicenter comparison of transperitoneal and retroperitoneal approaches. *Am Surg* 77:409-416
72. Rubinstein M, Gill IS, Aron M, Kilciler M, Meraney AM, Finelli A, Moinzadeh A, Ukimura O, Desai MM, Kaouk J, Bravo E (2005) Prospective, randomized comparison of transperitoneal versus retroperitoneal laparoscopic adrenalectomy. *J Urol* 174:442-445; discussion 445
73. Brunt LM, Molmenti EP, Kerbl K, Soper NJ, Stone AM, Clayman RV (1993) Retroperitoneal endoscopic adrenalectomy: an experimental study. *Surg Laparosc*



Endosc 3:300-306

74. Walz MK, Peitgen K, Walz MV, Hoermann R, Saller B, Giebler RM, Jockenhovel F, Philipp T, Broelsch CE, Eigler FW, Mann K (2001) Posterior retroperitoneoscopic adrenalectomy: lessons learned within five years. *World J Surg* 25:728-734
75. Perrier ND, Kennamer DL, Bao R, Jimenez C, Grubbs EG, Lee JE, Evans DB (2008) Posterior retroperitoneoscopic adrenalectomy: preferred technique for removal of benign tumors and isolated metastases. *Ann Surg* 248:666-674
76. Suzuki K, Kageyama S, Hirano Y, Ushiyama T, Rajamahanty S, Fujita K (2001) Comparison of 3 surgical approaches to laparoscopic adrenalectomy: a nonrandomized, background matched analysis. *J Urol* 166:437-443
77. Lezoche E, Guerrieri M, Feliciotti F, Paganini AM, Perretta S, Baldarelli M, Bonjer J, Miccoli P (2002) Anterior, lateral, and posterior retroperitoneal approaches in endoscopic adrenalectomy. *Surg Endosc* 16:96-99
78. Gockel I, Vetter G, Heintz A, Junginger T (2005) Endoscopic adrenalectomy for pheochromocytoma: difference between the transperitoneal and retroperitoneal approaches in terms of the operative course. *Surg Endosc* 19:1086-1092
79. Naya Y, Nagata M, Ichikawa T, Amakasu M, Omura M, Nishikawa T, Yamaguchi K, Ito H (2002) Laparoscopic adrenalectomy: comparison of transperitoneal and retroperitoneal approaches. *BJU Int* 90:199-204
80. Lezoche E, Guerrieri M, Crosta F, Lezoche G, Baldarelli M, Campagnacci R (2008) Flank approach versus anterior sub-mesocolic access in left laparoscopic adrenalectomy: a prospective randomized study. *Surg Endosc* 22:2373-2378
81. Sasagawa I, Suzuki Y, Itoh K, Izumi T, Miura M, Suzuki H, Tomita Y (2003) Posterior retroperitoneoscopic partial adrenalectomy: clinical experience in 47 procedures. *Eur Urol* 43:381-385
82. Horgan S, Vanuno D (2001) Robots in laparoscopic surgery. *J Laparoendosc Adv Surg Tech A* 11:415-419
83. Brunaud L, Ayav A, Zarnegar R, Rouers A, Klein M, Boissel P, Bresler L (2008) Prospective evaluation of 100 robotic-assisted unilateral adrenalectomies. *Surgery* 144:995-1001; discussion 1001
84. Brunaud L, Bresler L, Ayav A, Zarnegar R, Raphoz AL, Levan T, Weryha G, Boissel P (2008) Robotic-assisted adrenalectomy: what advantages compared to lateral transperitoneal laparoscopic adrenalectomy? *Am J Surg* 195:433-438
85. Nordenstrom E, Wester Dahl J, Hallgrimsson P, Bergenfelz A (2011) A prospective study of 100 robotically assisted laparoscopic adrenalectomies. *J Robot Surg* 5:127-131
86. Giulianotti PC, Buchs NC, Addeo P, Bianco FM, Ayloo SM, Caravaglios G, Coratti A (2011) Robot-assisted adrenalectomy: a technical option for the surgeon? *Int J Med Robot* 7:27-32
87. Winter JM, Talamini MA, Stanfield CL, Chang DC, Hundt JD, Dackiw AP, Campbell KA, Schulick RD (2006) Thirty robotic adrenalectomies: a single institution's experience. *Surg Endosc* 20:119-124
88. Morino M, Beninca G, Giraud G, Del Genio GM, Rebecchi F, Garrone C (2004) Robot-assisted vs laparoscopic adrenalectomy: a prospective randomized controlled trial. *Surg Endosc* 18:1742-1746
89. Asher KP, Gupta GN, Boris RS, Pinto PA, Linehan WM, Bratslavsky G (2011) Robot-assisted laparoscopic partial adrenalectomy for pheochromocytoma: the National



- Cancer Institute technique. *Eur Urol* 60:118-124
90. Berber E, Mitchell J, Milas M, Siperstein A (2010) Robotic posterior retroperitoneal adrenalectomy: operative technique. *Arch Surg* 145:781-784
  91. Rane A, Cindolo L, Schips L, De Sio M, Autorino R (2011) Laparoendoscopic single site (LESS) adrenalectomy: Technique and outcomes. *World J Urol* April 26 [Epub ahead of print].
  92. Ishida M, Miyajima A, Takeda T, Hasegawa M, Kikuchi E, Oya M (2010) Technical difficulties of transumbilical laparoendoscopic single-site adrenalectomy: comparison with conventional laparoscopic adrenalectomy. *World J Urol* December 28 [Epub ahead of print].
  93. Jeon HG, Jeong W, Oh CK, Lorenzo EI, Ham WS, Rha KH, Han WK (2010) Initial experience with 50 laparoendoscopic single site surgeries using a homemade, single port device at a single center. *J Urol* 183:1866-1871
  94. Jeong BC, Park YH, Han DH, Kim HH (2009) Laparoendoscopic single-site and conventional laparoscopic adrenalectomy: a matched case-control study. *J Endourol* 23:1957-1960
  95. Chung SD, Huang CY, Wang SM, Tai HC, Tsai YC, Chueh SC (2011) Laparoendoscopic single-site (LESS) retroperitoneal adrenalectomy using a homemade single-access platform and standard laparoscopic instruments. *Surg Endosc* 25:1251-1256
  96. Agha A, Hornung M, Iesalnieks I, Glockzin G, Schlitt HJ (2010) Single-incision retroperitoneoscopic adrenalectomy and single-incision laparoscopic adrenalectomy. *J Endourol* 24:1765-1770
  97. Walz MK, Groeben H, Alesina PF (2010) Single-access retroperitoneoscopic adrenalectomy (SARA) versus conventional retroperitoneoscopic adrenalectomy (CORA): a case-control study. *World J Surg* 34:1386-1390
  98. Shi TP, Zhang X, Ma X, Li HZ, Zhu J, Wang BJ, Gao JP, Cai W, Dong J (2011) Laparoendoscopic single-site retroperitoneoscopic adrenalectomy: a matched-pair comparison with the gold standard. *Surg Endosc* 25:2117-2124
  99. van Heerden JA, Sizemore GW, Carney JA, Brennan MD, Sheps SG (1985) Bilateral subtotal adrenal resection for bilateral pheochromocytomas in multiple endocrine neoplasia, type IIa: a case report. *Surgery* 98:363-366
  100. Walz MK, Gwosdz R, Levin SL, Alesina PF, Suttorp AC, Metz KA, Wenger FA, Petersenn S, Mann K, Schmid KW (2008) Retroperitoneoscopic adrenalectomy in Conn's syndrome caused by adrenal adenomas or nodular hyperplasia. *World J Surg* 32:847-853
  101. Diner EK, Franks ME, Behari A, Linehan WM, Walther MM (2005) Partial adrenalectomy: the National Cancer Institute experience. *Urology* 66:19-23
  102. Nakada T, Kubota Y, Sasagawa I, Yagisawa T, Watanabe M, Ishigooka M (1995) Therapeutic outcome of primary aldosteronism: adrenalectomy versus enucleation of aldosterone-producing adenoma. *J Urol* 153:1775-1780
  103. Brauckhoff M, Gimm O, Thanh PN, Bar A, Ukkat J, Brauckhoff K, Bonsch T, Dralle H (2003) Critical size of residual adrenal tissue and recovery from impaired early postoperative adrenocortical function after subtotal bilateral adrenalectomy. *Surgery* 134:1020-1027; discussion 1027-1028
  104. Walz MK, Peitgen K, Diesing D, Petersenn S, Janssen OE, Philipp T, Metz KA, Mann K,



- Schmid KW, Neumann HP (2004) Partial versus total adrenalectomy by the posterior retroperitoneoscopic approach: early and long-term results of 325 consecutive procedures in primary adrenal neoplasias. *World J Surg* 28:1323-1329
105. Lee JE, Curley SA, Gagel RF, Evans DB, Hickey RC (1996) Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. *Surgery* 120:1064-1070; discussion 1070-1061
106. Yip L, Lee JE, Shapiro SE, Waguespack SG, Sherman SI, Hoff AO, Gagel RF, Arens JF, Evans DB (2004) Surgical management of hereditary pheochromocytoma. *J Am Coll Surg* 198:525-534; discussion 534-525
107. Brauckhoff M, Stock K, Stock S, Lorenz K, Sekulla C, Brauckhoff K, Thanh PN, Gimm O, Spielmann RP, Dralle H (2008) Limitations of intraoperative adrenal remnant volume measurement in patients undergoing subtotal adrenalectomy. *World J Surg* 32:863-872
108. Fernandez-Cruz L, Taura P, Saenz A, Benarroch G, Sabater L (1996) Laparoscopic approach to pheochromocytoma: hemodynamic changes and catecholamine secretion. *World J Surg* 20:762-768; discussion 768
109. Zhang X, Wang B, Ma X, Zhang G, Shi T, Ju Z, Wang C, Li H, Ai X, Fu B (2009) Laparoscopic adrenalectomy for beginners without open counterpart experience: initial results under staged training. *Urology* 73:1061-1065
110. Vassiliou MC, Laycock WS (2009) Laparoscopic adrenalectomy for pheochromocytoma: take the vein last? *Surg Endosc* 23:965-968
111. Guerrieri M, Crosta F, De Sanctis A, Baldarelli M, Lezoche G, Campagnacci R (2008) Use of the electrothermal bipolar vessel system (EBVS) in laparoscopic adrenalectomy: a prospective study. *Surg Endosc* 22:141-145
112. Surgit O (2010) Clipless and sutureless laparoscopic adrenalectomy carried out with the LigaSure device in 32 patients. *Surg Laparosc Endosc Percutan Tech* 20:109-113
113. Miller BS, Ammori JB, Gauger PG, Broome JT, Hammer GD, Doherty GM (2010) Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. *World J Surg* 34:1380-1385
114. Leboulleux S, Deandreis D, Al Ghuzlan A, Auperin A, Goere D, Dromain C, Elias D, Caillou B, Travagli JP, De Baere T, Lumbroso J, Young J, Schlumberger M, Baudin E (2010) Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? *Eur J Endocrinol* 162:1147-1153
115. Porpiglia F, Miller BS, Manfredi M, Fiori C, Doherty GM (2011) A debate on laparoscopic versus open adrenalectomy for adrenocortical carcinoma. *Horm Cancer* 2:372-377
116. Brix D, Allolio B, Fenske W, Agha A, Dralle H, Jurowich C, Langer P, Mussack T, Nies C, Riedmiller H, Spahn M, Weismann D, Hahner S, Fassnacht M (2010) Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. *Eur Urol* 58:609-615
117. Shen WT, Sturgeon C, Duh QY (2005) From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors. *J Surg Oncol* 89:186-192
118. Adler JT, Mack E, Chen H (2007) Equal oncologic results for laparoscopic and open resection of adrenal metastases. *J Surg Res* 140:159-164
119. Heniford BT, Arca MJ, Walsh RM, Gill IS (1999) Laparoscopic adrenalectomy for cancer. *Semin Surg Oncol* 16:293-306
120. Sarela AI, Murphy I, Coit DG, Conlon KC (2003) Metastasis to the adrenal gland: the emerging role of laparoscopic surgery. *Ann Surg Oncol* 10:1191-1196



121. Sebag F, Calzolari F, Harding J, Sierra M, Palazzo FF, Henry JF (2006) Isolated adrenal metastasis: the role of laparoscopic surgery. *World J Surg* 30:888-892
122. Miccoli P, Materazzi G, Mussi A, Lucchi M, Massi M, Berti P (2004) A reappraisal of the indications for laparoscopic treatment of adrenal metastases. *J Laparoendosc Adv Surg Tech A* 14:139-145
123. Muth A, Persson F, Jansson S, Johanson V, Ahlman H, Wangberg B (2010) Prognostic factors for survival after surgery for adrenal metastasis. *Eur J Surg Oncol* 36:699-704
124. Wu HY, Yu Y, Xu LW, Li XD, Yu DM, Zhang ZG, Li GH (2011) Transperitoneal laparoscopic adrenalectomy for adrenal metastasis. *Surg Laparosc Endosc Percutan Tech* 21:271-274
125. Ramacciato G, Mercantini P, La Torre M, Di Benedetto F, Ercolani G, Ravaioli M, Piccoli M, Melotti G (2008) Is laparoscopic adrenalectomy safe and effective for adrenal masses larger than 7 cm? *Surg Endosc* 22:516-521
126. Hobart MG, Gill IS, Schweizer D, Sung GT, Bravo EL (2000) Laparoscopic adrenalectomy for large-volume (> or = 5 cm) adrenal masses. *J Endourol* 14:149-154
127. Boylu U, Oommen M, Lee BR, Thomas R (2009) Laparoscopic adrenalectomy for large adrenal masses: pushing the envelope. *J Endourol* 23:971-975
128. Naya Y, Suzuki H, Komiya A, Nagata M, Tobe T, Ueda T, Ichikawa T, Igarashi T, Yamaguchi K, Ito H (2005) Laparoscopic adrenalectomy in patients with large adrenal tumors. *Int J Urol* 12:134-139
129. Zografos GN, Farfaras A, Vasiliadis G, Pappa T, Aggeli C, Vasilatou E, Kaltsas G, Piaditis G (2010) Laparoscopic resection of large adrenal tumors. *JLS* 14:364-368
130. Sharma R, Ganpule A, Veeramani M, Sabnis RB, Desai M (2009) Laparoscopic management of adrenal lesions larger than 5 cm in diameter. *Urol J* 6:254-259
131. Cheah WK, Clark OH, Horn JK, Siperstein AE, Duh QY (2002) Laparoscopic adrenalectomy for pheochromocytoma. *World J Surg* 26:1048-1051
132. Gagner M, Breton G, Pharand D, Pomp A (1996) Is laparoscopic adrenalectomy indicated for pheochromocytomas? *Surgery* 120:1076-1079; discussion 1079-1080
133. Kebebew E, Duh QY (1998) Benign and malignant pheochromocytoma: diagnosis, treatment, and follow-Up. *Surg Oncol Clin N Am* 7:765-789
134. Pacak K (2007) Preoperative management of the pheochromocytoma patient. *J Clin Endocrinol Metab* 92:4069-4079
135. Perry RR, Keiser HR, Norton JA, Wall RT, Robertson CN, Travis W, Pass HI, Walther MM, Linehan WM (1990) Surgical management of pheochromocytoma with the use of metyrosine. *Ann Surg* 212:621-628
136. Steinsapir J, Carr AA, Prisant LM, Bransome ED, Jr. (1997) Metyrosine and pheochromocytoma. *Arch Intern Med* 157:901-906
137. Eigelberger MS, Duh QY (2001) Pheochromocytoma. *Curr Treat Options Oncol* 2:321-329
138. Shapiro B, Fig LM (1989) Management of pheochromocytoma. *Endocrinol Metab Clin North Am* 18:443-481
139. Williams DT, Dann S, Wheeler MH (2003) Pheochromocytoma--views on current management. *Eur J Surg Oncol* 29:483-490
140. Manger WM, Gifford RW, Jr. (1993) Pheochromocytoma: current diagnosis and management. *Cleve Clin J Med* 60:365-378
141. Mannelli M (2006) Management and treatment of pheochromocytomas and



- paragangliomas. *Ann N Y Acad Sci* 1073:405-416
142. Hull CJ (1986) Pheochromocytoma. Diagnosis, preoperative preparation and anaesthetic management. *Br J Anaesth* 58:1453-1468
  143. Fernandez-Cruz L, Saenz A, Taura P, Sabater L, Astudillo E, Fontanals J (1998) Helium and carbon dioxide pneumoperitoneum in patients with pheochromocytoma undergoing laparoscopic adrenalectomy. *World J Surg* 22:1250-1255
  144. Feldman JM, Blalock JA, Fagraeus L, Miller JN, Farrell RE, Wells SA, Jr. (1978) Alterations in plasma norepinephrine concentration during surgical resection of pheochromocytoma. *Ann Surg* 188:758-768
  145. Marty J, Desmonts JM, Chalaux G, Fischler M, Michon F, Mazze RI, Comoy E (1985) Hypertensive responses during operation for pheochromocytoma: a study of plasma catecholamine and haemodynamic changes. *Eur J Anaesthesiol* 2:257-264
  146. Newell KA, Prinz RA, Brooks MH, Glisson SN, Barbato AL, Freeark RJ (1988) Plasma catecholamine changes during excision of pheochromocytoma. *Surgery* 104:1064-1073
  147. de La Chapelle A, Deghmani M, Dureuil B (1998) Peritoneal insufflation can be a critical moment in the laparoscopic surgery of pheochromocytoma. *Ann Fr Anesth Reanim* 17:1184-1185
  148. Rose CE, Jr., Althaus JA, Kaiser DL, Miller ED, Carey RM (1983) Acute hypoxemia and hypercapnia: increase in plasma catecholamines in conscious dogs. *Am J Physiol* 245:H924-929
  149. Kim AW, Quiros RM, Maxhimer JB, El-Ganzouri AR, Prinz RA (2004) Outcome of laparoscopic adrenalectomy for pheochromocytomas vs aldosteronomas. *Arch Surg* 139:526-529; discussion 529-531
  150. John H, Ziegler WH, Hauri D, Jaeger P (1999) Pheochromocytomas: can malignant potential be predicted? *Urology* 53:679-683
  151. Goldstein RE, O'Neill JA, Jr., Holcomb GW, 3rd, Morgan WM, 3rd, Neblett WW, 3rd, Oates JA, Brown N, Nadeau J, Smith B, Page DL, Abumrad NN, Scott HW, Jr. (1999) Clinical experience over 48 years with pheochromocytoma. *Ann Surg* 229:755-764; discussion 764-756
  152. Guerrieri M, Campagnacci R, De Sanctis A, Baldarelli M, Coletta M, Perretta S (2008) The learning curve in laparoscopic adrenalectomy. *J Endocrinol Invest* 31:531-536
  153. Goitein D, Mintz Y, Gross D, Reissman P (2004) Laparoscopic adrenalectomy: ascending the learning curve. *Surg Endosc* 18:771-773
  154. van Heerden JA, Roland CF, Carney JA, Sheps SG, Grant CS (1990) Long-term evaluation following resection of apparently benign pheochromocytoma(s)/paraganglioma(s). *World J Surg* 14:325-329
  155. Plouin PF, Gimenez-Roqueplo AP (2006) Initial work-up and long-term follow-up in patients with pheochromocytomas and paragangliomas. *Best Pract Res Clin Endocrinol Metab* 20:421-434
  156. Thompson LD (2002) Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. *Am J Surg Pathol* 26:551-566
  157. Strong VE, Kennedy T, Al-Ahmadie H, Tang L, Coleman J, Fong Y, Brennan M, Ghossein RA (2008) Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. *Surgery* 143:759-768



158. Gao B, Meng F, Bian W, Chen J, Zhao H, Ma G, Shi B, Zhang J, Liu Y, Xu Z (2006) Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas. *Urology* 68:282-286
159. Wu D, Tischler AS, Lloyd RV, DeLellis RA, de Krijger R, van Nederveen F, Nose V (2009) Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score. *Am J Surg Pathol* 33:599-608
160. Agarwal A, Mehrotra PK, Jain M, Gupta SK, Mishra A, Chand G, Agarwal G, Verma AK, Mishra SK, Singh U (2010) Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy? *World J Surg* 34:3022-3028
161. Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A, Patel S, Waguespack S, Jimenez C (2011) Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. *J Clin Endocrinol Metab* 96:717-725
162. Park J, Song C, Park M, Yoo S, Park SJ, Hong S, Hong B, Kim CS, Ahn H (2011) Predictive characteristics of malignant pheochromocytoma. *Korean J Urol* 52:241-246
163. Barczynski M, Konturek A, Golkowski F, Cichon S, Huszno B, Peitgen K, Walz MK (2007) Posterior retroperitoneoscopic adrenalectomy: a comparison between the initial experience in the invention phase and introductory phase of the new surgical technique. *World J Surg* 31:65-71
164. Gil-Cardenas A, Cordon C, Gamino R, Rull JA, Gomez-Perez F, Pantoja JP, Herrera MF (2008) Laparoscopic adrenalectomy: lessons learned from an initial series of 100 patients. *Surg Endosc* 22:991-994

**Table 1. Comparative studies on laparoscopic versus open adrenalectomy**

Author/ Year	# of patients	Laparo scopic technique	EBL (ml)	Length of stay (days)	OR time (minutes)	Tumor Size (cm)	Morbidity (%)	Mortality (%)
Lang B/2008 [61]	108	Retrope ritoneal						